Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug
pharmaphorum
JULY 15, 2022
The substance patent expired in 2007. Things became litigious in 2017, when a Delaware court found that Teva’s label for its generic encouraged doctors to use the drug to treat heart failure in a way that infringed GSK’s RE40,000 patent, which was reissued by the Patent and Trademark Office (PTO) in 2008.
52 
Let's personalize your content